Published in Gene Therapy Weekly, January 20th, 2011
"Targeted inactivation of MEK alone using pharmacological inhibitors or siRNAs resulted in reduced sphere formation of both cell line-and patient-derived glioblastoma CSLCs, accompanied by their...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.